标题
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma
作者
关键词
-
出版物
NEW ENGLAND JOURNAL OF MEDICINE
Volume 388, Issue 11, Pages 1002-1014
出版商
Massachusetts Medical Society
发表日期
2023-02-11
DOI
10.1056/nejmoa2213614
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Treatment Options for Patients With Heavily Pretreated Relapsed and Refractory Multiple Myeloma
- (2022) Meletios-Athanasios Dimopoulos et al. Clinical Lymphoma Myeloma & Leukemia
- LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma
- (2022) Maria-Victoria Mateos et al. LEUKEMIA
- Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma
- (2021) Nikhil C. Munshi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Perspectives on Drug Development in Multiple Myeloma—Looking Forward to 2025
- (2021) Peter M. Voorhees et al. CLINICAL CANCER RESEARCH
- Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.
- (2021) Larry D. Anderson et al. JOURNAL OF CLINICAL ONCOLOGY
- Future Directions in Maintenance Therapy in Multiple Myeloma
- (2021) Sarah A. Holstein et al. Journal of Clinical Medicine
- Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia
- (2020) Talha Badar et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy
- (2019) Ujjawal H. Gandhi et al. LEUKEMIA
- Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
- (2019) Noopur Raje et al. NEW ENGLAND JOURNAL OF MEDICINE
- Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies
- (2019) Jiali Cheng et al. Frontiers in Oncology
- Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma
- (2018) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study
- (2016) Meletios A Dimopoulos et al. LANCET ONCOLOGY
- International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma
- (2016) Shaji Kumar et al. LANCET ONCOLOGY
- Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Philippe Moreau et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma
- (2015) Sagar Lonial et al. NEW ENGLAND JOURNAL OF MEDICINE
- Current concepts in the diagnosis and management of cytokine release syndrome
- (2014) D. W. Lee et al. BLOOD
- B-cell Maturation Antigen Is a Promising Target for Adoptive T-cell Therapy of Multiple Myeloma
- (2013) R. O. Carpenter et al. CLINICAL CANCER RESEARCH
- Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival
- (2012) Eric Sanchez et al. BRITISH JOURNAL OF HAEMATOLOGY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now